Home > Brain Waves
About this author
Zack Lynch Zack Lynch is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT,Center for Cognitive Liberty & Ethics, the InnerSpace Foundation, the Center for Neuroeconomic Studies and SocialText, a social software company. His book on how brain science is changing our world will be available July 2009. Please send newsworthy items or feedback - to Zack Lynch.
Receive by email

GUEST AUTHOR ARCHIVES
NEUROTECH REPORT
120_NIR_2008_Cover_120.jpg 2008 Industry Report Available
NEUROTECH NEWS
NEUROTECH INDEX
INDUSTRY REPORT 2008
INVESTMENT NEWSLETTERS
BLOGS I READ
HealthBlog
Neurodudes
Mind Hacks
Neuro-journalism Mill
Neurolearning
Ross Mayfield
Future Pundit
Marginal Revolution
Pat Kane
Pipeline
Virginia Postrel
Brad Delong - Econ
Business Pundit
Tech Central
Steven Johnson
Technorati Profile
NEURORESOURCE LINKS
Affective Computing
Journal of Bioethics
BioSpace
Bus. 2.0 Neurotech
Cerebrum
Drug Discovery World
Emotions Research
European Brain Council
Faster Cures
Neuroscience Info
Gyre-Neurotech
NIO
Neurotech market
Int'l Brain Research
Neuro-Jobs
McGovern MIT Brain Research
Neuroeconomics
Neuroethics at Penn
Neuroethics
Neuroesthetics
NeuroInsights
Neurosociety Analysis
Nobel
PharmaPortal
Play Ethic
Rutgers Memory Lab
NEWS SOURCES
Bio-IT World
BioTech Today
BusinessWeek
Corante Biotech
Discover
Economist
Forbes
Fortune
Genetic Engineering News
GenomeWeb
Human Nature
J. Neurobio Learning
J. Neuroscience
J. Complexity Psych.
Nature-Neuroscience
Nature-NeuroPharma
Nature- NeuroNews
NY Times - Science
The Scientist
Reason Magazine
Science Magazine
Seed Magazine
ORGANIZATIONS
BLTC
Bionomics
CDC
Cold Spring Harbor
Center for Cognitive Liberty
Dana
Gruter Institute
Keck-UCSF
NBIC
Neuroethics at Penn
US Bioethics
NIO
NeuroInsights
NCBI
NCGR
NIH
NIMH
Neuroscience Society
Scripps Research
Pubmed
Weizmann Institute
Whitehead Institute
Mind Brain






Subscribe with Bloglines
Check out Jevon MacDonald on the "uncertain future of blogging"


Brain Waves
September 27, 2004
ADHD - NeuroImaging Used to Understand $77B problemEmail This EntryPrint This Entry
Posted by Zack

Do you ever lose focus after working for several hours on a project? Are there times when you just can't seem to concentrate anymore? If you answered yes to these questions then you are probably normal. But what is normal? And for that matter what is attention deficit "hyperactivity" disorder, ADHD? According to the DSM, there are sixteen behavioral differences between the two groups.

In a recent Harvard study claimed that ADHD costs Americans suffering from the condition about $77 billion in lost income a year, more than the total costs of drug abuse or depression. Usually considered a childhood disorder, ADHD affects about 8 million U.S. adults and is linked to job loss, lower income, higher divorce rates and more driving accidents, said Dr. Joseph Biederman, professor of psychiatry at Harvard Medical School.

To help understand how the current set of attention focusing cogniceuticals impact normal brains versus those with ADHD, the NIMH recently approved a study that would give normal children and children with ADHD dextromethylphenadate and use neuroimaging techniques to see if there is a different response.

Since there are currently no biomarkers or neuroimaging tests that define ADHD from a neurological perspective, some argue that it doesn't exist. This new trial would add magnetic resonance images to map any differences in brain activation patterns, even though previous studies that attempted to use neuroimaging to define the disorder remain controversial.

While giving normal children these performance focusing cogniceuticals is causing a bit of an ethical stir, Judith Rapoport, chief of child psychology at NIMH, conducted a similar trial 20 years ago. The same stimulant was given to children at a higher dose. Researchers looked only at how the stimulant changed children's behavior as they performed tasks. The stimulant improved attention span in the children, regardless of whether they had ADHD. This time, I guess we'll see where specifically there might be a difference in brain activation between the groups and see if we can make a dent in this profoundly disruptive problem.


Category: Neuropharma


COMMENTS
chris on September 28, 2004 12:03 AM writes...

As somone diagnosed with ADD, I can vouch for the improved ability to concentrate through approprite medication. Another key element to my coping is a relentless search to understand my own personal flavor of the disorder and how various treatment may help.

One group that is at the forefront of this rearch is the amen clinic. I recommend the website, www.brainplace.org, to learn more and to view a vast catalog of brain images from a variety of diagnosis and how they compare to healthy brain scans.

The CHADD organization is another excellent resource. Their website is www.chadd.org.

Permalink to Comment


TRACKBACKS
TrackBack URL: http://www.corante.com/cgi-bin/mt/mt-tb.cgi/4706
ADHD - NeuroImaging Used to Understand $77B problem: Corante > Brain Waves > from RelentlesslyOptimistic ADHD - NeuroImaging Used to Understand $77B problem: Corante [Read More]

Tracked on November 28, 2004 09:54 AM




POST A COMMENT
Name:

Email:

URL:

Comments:

Remember personal info?



EMAIL THIS ENTRY TO A FRIEND
Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES